Beta Bionics (BBNX) Stock Analysis & Winston Score
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin with
Winston Score: 25/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $17.29
Market Cap: $770M
Sector: Healthcare
Industry: Medical - Equipment & Services
Exchange: NASDAQ
